US General Anesthesia Drugs Market Size to Hit Around USD 4.37 Bn By 2032
The US general anesthesia drugs market size was exhibited at USD 3.1 billion in 2022 and is projected to hit around USD 4.37 billion by 2032, growing at a CAGR of 3.5% during the forecast period 2023 to 2032.
Key Takeaways:
The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The rising prevalence of cancer, rapid growth in geriatric population, and increasing number of emergency surgeries are some of the major factors driving the growth of the US general anesthesia drugs.
US General Anesthesia Drugs Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 3.2 Billion |
| Market Size by 2032 | USD 4.37 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 3.5% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Route of Administration, End User, Company Type |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Baxter International Inc. (US), Pfizer Inc. (US), AbbVie (US), Par Pharmaceutical (US), Viatris/Mylan (US), Novartis AG (US), Abbott Laboratories (US), AstraZeneca plc (US), Gilead Sciences, Inc. (US),Heritage Pharmaceuticals Inc. (US), Akorn (US), and Apotex |
US General Anesthesia Drugs Market Dynamics
Driver: Rising prevalence of cancer
The prevalence of cancer has increased significantly in the US over the last few decades. According to the National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors in the US. The number of cancer survivors is projected to increase to 28.2 million by 2032. The most common cancers (listed in descending order according to estimated new cases in 2020) are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. Prostate, lung, and colorectal cancers accounted for 45% of all cancers diagnosed in men in 2020. Whereas, in women, breast, lung, and colorectal cancer accounted for over 50% of all new cancers diagnosed in 2020. The rising prevalence of cancer will lead to a rise in the number of surgeries as for many tumors, cancer surgery is the best chance for a cure, especially if the cancer is localized. Thus, the growing prevalence of cancer will fuel the growth of the US general anesthesia market, as general anesthesia is commonly used for surgical procedures to treat cancer.
Restraint: Risks associated with general anesthesia in pediatric patients and pregnant women
The use of pharmacologic agents, including general anesthesia drugs, in pediatric patients, warrants special considerations. In comparison to adults, infants and young children respond differently to anesthesia medications due to many factors, including body composition, protein binding, body temperature, distribution of cardiac output, and functional maturity of the liver and kidneys.
According to various studies, the use of general anesthetics and sedation drugs in pregnant animals and young animals for more than 3 hours caused widespread loss of nerve cells in the brain. Recent human studies suggest that a single, relatively short exposure to general anesthetics and sedation drugs in infants or toddlers is unlikely to have negative effects on behavior or learning.
In view of the same, the US FDA issued new warnings in April 2017, related to the use of general anesthetics and sedation drugs in young children and pregnant women. General anesthetics and sedation drugs are necessary for patients, including young children and pregnant women, who require surgery or other painful and stressful procedures. The US FDA has warned about the repeated or lengthy use of general anesthetics and sedation drugs during surgeries or procedures in children younger than three years and pregnant women. The potential risk associated with the use of general anesthesia drugs in young children and pregnant women can lead to a decrease in the uptake of general anesthetics by healthcare professionals and thus may hinder market growth
Opportunity: Patent expiry of Lusedra
Lusedra (fospropofol disodium) is an intravenous sedative-hypnotic agent. It was approved by the FDA in 2008 for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures. This molecule will go off-patent by 2022. The patent expiration of this molecule will pave the way for generic drugs to enter the US market, which is expected to offer a significant growth outlook for the key players operating in the market.
Some of the prominent players in the US General Anesthesia Drugs Market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the US General Anesthesia Drugs market.
By Route of Administration
By End User
By Company Type
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers